Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer

1442.2000 -13.80 (-0.95%)

NSE Apr 07, 2026 15:31 PM

52W high on Mar 17, 2026

Volume: 83,654

Ipca Laboratories Ltd.

13 Nov 2025

1442.20

-0.95%

Beat on estimates; DF/API drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) delivered slightly better-than-expected revenue in 2QFY26, while EBITDA/PAT beat our estimates by 18%/22%.

Number of FII/FPI investors decreased from 254 to 248 in Dec 2025 qtr